Evidence map›Paper›PMID 42151133›Full record

ArticleNature communications2026

De novo design of a macrocycle-induced dimerization system for cellular control.

Stephanie Hanna, Patrick J Salveson, Basile Wicky, Madison A Kennedy, Derrick R Hicks, Carolina Moller, Suna Cheng, Xinting Li, Mohamad Abedi, Brian Coventry and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors.

Stephanie HannaDepartment of Chemistry, University of Washington, Seattle, WA, USA.
Patrick J SalvesonInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Basile WickyInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Madison A KennedyInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-3422-9172
Derrick R HicksInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Carolina MollerInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3116-875X
Suna ChengInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Xinting LiInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Mohamad AbediInstitute for Protein Design, University of Washington, Seattle, WA, USA.
Brian CoventryInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-6910-6255
Meerit Y SaidInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0002-3150-3140
Asim K BeraInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-9473-2912
Alex KangInstitute for Protein Design, University of Washington, Seattle, WA, USA.ORCID http://orcid.org/0000-0001-5487-0499
Barry L StoddardDivision of Basic Sciences, Fred Hutchinson Cancer Center, Seattle, WA, USA.ORCID http://orcid.org/0000-0003-2250-9601
David BakerInstitute for Protein Design, University of Washington, Seattle, WA, USA. dabaker@uw.edu.ORCID http://orcid.org/0000-0001-7896-6217

Funding

Project 4: Novel reagent development to enable molecular characterizationU19AG065156 · NIA · UNIVERSITY OF WASHINGTON · PI HOOFNAGLE, ANDREW N · 2020 to 2024
$15.9M
De Novo Design of Minibinder Antagonists for COVID-19 and Future PandemicsR01AI160052 · NIAID · UNIVERSITY OF WASHINGTON · PI BAKER, DAVID, FULLER, DEBORAH H. · 2021 to 2025
$3.5M
Acquisition of a Rigaku XtaLAB Synergy-R macromolecular diffraction instrumentation at Fred Hutchinson Cancer Research CenterS10OD028581 · OD · FRED HUTCHINSON CANCER RESEARCH CENTER · PI STODDARD, BARRY L. · 2020 to 2020
$600k
Gates Foundation INV-043758NIAID NIH HHS R01 AI160052NIA NIH HHS U19 AG065156NIH HHS S10 OD028581
6 · The paper itself

Abstract

Investigating and manipulating cellular events requires precise control of protein function. To enable control over cellular processes, we set out to design a chemically induced dimerization (CID) system consisting of a de novo-designed ligand and protein pair. Here, we describe the design of a C2 symmetric membrane-permeable macrocyclic peptide and a cognate protein homodimer which binds the macrocycle through a large interface with both chains. The designed homodimer binds the macrocycle with a K

Indexed as

Macrocyclic CompoundsPeptidesProtein MultimerizationAnimalsCrystallography, X-RayDimerizationHumansLigandsLuciferasesModels, MolecularProtein BindingLigandsLuciferasesMacrocyclic CompoundsPeptides

Identifiers

PMID42151133
PMCPMC13385886

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.